Advisory Board

  • Prof. Stephan Ludwig, Ph.D. (Chair), Universität D-Münster

    Head of Institute of Molecular Virology at Westfälische Wilhelms-Universität Münster, Germany. Co-inventor of the technology, globally renowned expert in influenza virus-cell interactions. Over 150 scientific publications and more than 10 patents.

  • Emilie Hofstetter, Strategy Consultant

    Senior management experience in Life Science Industry (i.e. Baxter). Track record of successful market entries and financing transactions.
  • Frans van Dalen, Board Member, Stichting Partcipatie Atriva

    Director of Stichting Partcipatie Atriva. Project Management, QA/QP, R&D and RA experience of more than 25 years regarding global development of generics, biosimilars and NBEs. More than 25 patents. Co-founder of Synthon Inc.

  • Paul Lelieveld, Board Member, Stichting Partcipatie Atriva

    Director of Stichting Partcipatie Atriva. Passionate entrepreneur in the field of innovation and building businesses who led investment rounds in several companies, and has invested for among others Wageningen Business Generator and Multifund. Board Member of Xenikos and Chairman of the GHI-Financials.

  • Frank Hensel Ph.D., Observer, Hightech-Gründer-Fonds GmbH

    Senior investment manager at Hightech-Gründer-Fonds with founding and management experience in the Biotech Industry and strong background in the development of monoclonal antibodies for cancer treatment.

  • Rudolf Erlemann, Ph.D. Observer, InSymbiosis

    Experienced preclinical drug developer with expertise in broad range of indications
  • 1

Address

Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com